Welcome to our dedicated page for Launch One Acquisition SEC filings (Ticker: LPAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Launch One Acquisition's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Launch One Acquisition's regulatory disclosures and financial reporting.
Launch One Acquisition Corp. (LPAA) filed its quarterly report and detailed progress toward its proposed merger with Minovia. For the quarter ended September 30, 2025, the SPAC reported net income of $2,011,042, driven largely by interest earned on its Trust Account. General and administrative expenses were $517,261, while interest on cash and marketable securities held in the Trust Account was $2,556,473.
The Trust Account held $243,082,744, equating to $10.56 per Public Share as of September 30, 2025. Management disclosed a working capital deficit of $332,033 and noted that the Combination Period governs the time to complete a business combination, with substantial doubt about the company’s ability to continue as a going concern if no deal closes within that period. The Minovia Business Combination Agreement sets total consideration of $180 million plus certain financing proceeds, payable in Pubco shares at the Redemption Price, and includes up to $57.5 million of contingent earnout shares, subject to specified share price or clinical milestones, and a $23 million minimum cash condition at closing.